Abivax SA (ABVX)
Euronext
Closed
Oct 12, 2026
Day's Range
77.3552 wk Range
60.45Overview - ABVX - Abivax SA
Key Statistics
Valuation
Enterprise Value
5.75B
P/E (Trailing)
‪-16.35‬
P/E (Forward)
‪-27.22‬
PEG Ratio
‪0.61‬
Price / Sales (TTM)
‪1,476.96‬
Price / Book
‪17.21‬
EV / EBITDA
‪-19.73‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪-8,617.93%‬
Return on Assets
‪-62.88%‬
Return on Equity
‪-252.34%‬
Ownership
Shares Outstanding
79.29M
Float
69.02M
Held by Insiders
‪3.78%‬
Held by Institutions
‪51.66%‬
Price stats
Beta
‪-0.23‬
50-Day Avg
‪96.09‬
200-Day Avg
‪100.79‬
Analyst Consensus
8 analysts
Average price target
‪€ 138.97‬Market Cap - ABVX - Abivax SA
Peers - ABVX - Abivax SA
Peer Comparison
Compared with companies in Biotechnology listed on Euronext.
Profile Summary - ABVX - Abivax SA
About
Abivax SA is a clinical-stage biotechnology company that develops therapeutics designed to harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Headquartered in Paris, France, and founded in 2013, the company operates in both France and the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
